These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Auto-SCT for AML in second remission: CALGB study 9620. Linker CA; Owzar K; Powell B; Hurd D; Damon LE; Archer LE; Larson RA; Bone Marrow Transplant; 2009 Sep; 44(6):353-9. PubMed ID: 19289999 [TBL] [Abstract][Full Text] [Related]
63. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734 [TBL] [Abstract][Full Text] [Related]
64. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129 [TBL] [Abstract][Full Text] [Related]
65. Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. Michaelis LC; Erba HP Curr Opin Hematol; 2015 Mar; 22(2):108-15. PubMed ID: 25603478 [TBL] [Abstract][Full Text] [Related]
66. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718 [TBL] [Abstract][Full Text] [Related]
67. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Staib P; Staltmeier E; Neurohr K; Cornely O; Reiser M; Schinköthe T Br J Haematol; 2005 Mar; 128(6):783-91. PubMed ID: 15755281 [TBL] [Abstract][Full Text] [Related]
68. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. Isidori A; Venditti A; Maurillo L; Buccisano F; Loscocco F; Manduzio P; Sparaventi G; Amadori S; Visani G Expert Rev Hematol; 2013 Dec; 6(6):767-84. PubMed ID: 24219553 [TBL] [Abstract][Full Text] [Related]
69. Acute myeloid leukaemia in the elderly: a review. Pollyea DA; Kohrt HE; Medeiros BC Br J Haematol; 2011 Mar; 152(5):524-42. PubMed ID: 21314823 [TBL] [Abstract][Full Text] [Related]
70. Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. Rosenblat TL; Jurcic JG Hematol Oncol Clin North Am; 2011 Dec; 25(6):1189-213. PubMed ID: 22093583 [TBL] [Abstract][Full Text] [Related]
73. Risk-adapted therapy of AML: the AMLCG experience. Kern W; Haferlach T; Schoch C; Sauerland MC; Heinecke A; Wörmann B; Berdel W; Büchner T; Hiddemann W Ann Hematol; 2004; 83 Suppl 1():S49-51. PubMed ID: 15124669 [TBL] [Abstract][Full Text] [Related]
74. The nature of remission in acute myeloblastic leukaemia. Powles RL; Selby PJ; Palu G; Morgenstern G; McElwain TJ; Clink HM; Alexander P Lancet; 1979 Sep; 2(8144):674-6. PubMed ID: 90762 [TBL] [Abstract][Full Text] [Related]
75. Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. Talbot DC; Montes A; Teh WL; Nandi A; Powles RL Hosp Med; 1998 Jul; 59(7):580-1. PubMed ID: 9798551 [No Abstract] [Full Text] [Related]
76. Is it time to revisit standard post-remission therapy? Stone RM Best Pract Res Clin Haematol; 2012 Dec; 25(4):437-41. PubMed ID: 23200540 [TBL] [Abstract][Full Text] [Related]
77. Management of AML: who do we really cure? Liesveld J Leuk Res; 2012 Dec; 36(12):1475-80. PubMed ID: 22938830 [TBL] [Abstract][Full Text] [Related]
78. Adult acute myeloid leukaemia. Smith M; Barnett M; Bassan R; Gatta G; Tondini C; Kern W Crit Rev Oncol Hematol; 2004 Jun; 50(3):197-222. PubMed ID: 15182826 [TBL] [Abstract][Full Text] [Related]